RELAPSING MULTIPLE SCLEROSIS

This study is testing whether an experimental drug called remibrutinib works better than an existing medication (teriflunomide) for people with relapsing multiple sclerosis. About 1,000 participants will take one of these medications for up to 30 months, with the option to contin…

This study is testing whether the drug Ocrevus can improve walking, balance, and leg strength in people with relapsing multiple sclerosis (MS) over one year. It will compare 60 participants taking Ocrevus to others taking different standard MS medications. Researchers will measur…

This study observes people with relapsing multiple sclerosis in Austria to see if starting the drug Ofatumumab (Kesimpta) early in their disease journey leads to better outcomes than starting it later. It follows 106 patients for two years, comparing those who start the drug soon…

This large Phase 3 study is testing whether a new oral drug called remibrutinib works better and is as safe as an existing standard oral medication (teriflunomide) for adults with relapsing multiple sclerosis (RMS). About 1011 participants will take one of the two drugs for up to…

This large, late-stage study is testing whether a new oral drug called fenebrutinib works better and is as safe as the established drug teriflunomide for adults with relapsing multiple sclerosis (RMS). About 750 participants are randomly assigned to take one of the two pills to s…

This large, late-stage study is testing whether an experimental oral drug called fenebrutinib works better and is as safe as an approved medication, teriflunomide, for adults with relapsing multiple sclerosis (RMS). About 746 participants will be randomly assigned to take one of …

This study is testing whether an experimental drug called fenebrutinib can reduce brain inflammation in people with relapsing multiple sclerosis. About 109 participants will receive either fenebrutinib or a placebo for 12 weeks, with researchers using brain scans to measure chang…

This study aims to collect long-term safety and effectiveness data for the drug ofatumumab in people with relapsing multiple sclerosis (MS). It follows nearly 1,900 patients who previously participated in a Novartis MS study to monitor their health over an extended period. The re…

This study is testing whether starting a medication called ocrelizumab very early after MS symptoms first appear can change signs of ongoing inflammation in the fluid around the brain and spinal cord. Researchers will treat 30 newly diagnosed adults and measure specific markers i…

This study is testing whether a new injectable medication called obexelimab can help control relapsing multiple sclerosis. It will involve 93 people with MS who will receive either the drug or a placebo for 12 weeks, followed by a longer period where everyone gets the drug. Resea…

This study follows up on previous trials to check the long-term safety and side effects of the drug tolebrutinib in adults with multiple sclerosis (MS). It will include about 2,500 people who were in earlier studies for relapsing or progressive forms of MS. The main goal is to mo…